TICKERNERD
Menu
AARDAARDHealthcare · Biotechnology

AARD Stock Forecast: Aardvark Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$5.06
+1.00% on the day

The 12 Wall Street analysts covering Aardvark Therapeutics, Inc. hold a median 12-month price target of $6 — +18.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$110.7M
Ticker Nerd rank
17 / 100
Median analyst target
$6.00
Analysts covering
12
Revenue$0.0
Operating income−$15.1M
Net income−$14.4M
Free cash flow−$17.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.7%
1M
−29.6%
YTD
−61.4%
1Y
−35.0%
From 52W high
−70.9%
From 52W low
+45.4%
$3
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AARD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aardvark Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
17 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
74
Revisions
58
Accruals
38
Issuance
33
Quality
29
Value
29
Growth
17
Momentum
11
Volatility
7

Size (74): Smaller than most of the companies we track.

Volatility (7): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AARD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AARD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26AARDHigh $28.00Median $6.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
6 Buy4 Hold2 Sell
Low $3.00Median $6.00High $28.00

The green dot is the last close — the median target sits +18.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 July 2026HC Wainwright & Co.ReiteratesNeutral$6.00
15 May 2026B. Riley SecuritiesMaintainsBuy—
15 May 2026B. Riley SecuritiesMaintainsBuy$8.00 → $7.00
15 May 2026BTIGDowngradeNeutral—
15 May 2026BTIGDowngradeNeutral—
15 May 2026Morgan StanleyDowngradeUnderweight$7.00 → $3.00
15 May 2026Morgan StanleyDowngradeUnderweight—
24 Mar 2026BTIGReiteratesBuy—
2 Mar 2026BTIGMaintainsBuy—
2 Mar 2026HC Wainwright & Co.DowngradeNeutral—
2 Mar 2026Morgan StanleyDowngradeEqual-Weight—
2 Mar 2026OppenheimerMaintainsOutperform—
2 Mar 2026RBC CapitalDowngradeSector Perform—
2 Mar 2026StifelDowngradeHold—
10 Feb 2026BTIGReiteratesBuy—
9 Feb 2026HC Wainwright & Co.ReiteratesBuy—
23 Dec 2025OppenheimerInitiatesOutperform—
12 Dec 2025William BlairInitiatesOutperform—
14 Nov 2025RBC CapitalMaintainsOutperform—
7 Nov 2025BTIGInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AARD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AARD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Aardvark Therapeutics, Inc. returned −35.0% against +17.5% for the S&P 500, dividends included.

AARD vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Oct 25Jan 26Apr 26Jul 26AARDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AARD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
1
Fundamentals

Aardvark Therapeutics, Inc. (AARD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.7×

Cheaper than 84% of US stocks

Price / sales
—
Price / book
1.5×

Cheaper than 55% of US stocks

EV / EBITDA
−0.5×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−66.0%

Higher than 18% of US stocks

Return on assets
−40.4%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aardvark Therapeutics, Inc. (AARD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aardvark Therapeutics, Inc. has a market value of $110.7M and an enterprise value of $39.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$69.9M.

  • Diluted earnings per share, trailing twelve months: $−3.21.

  • Free cash flow in the twelve months to 30 June 2026: −$69.4M.

  • Shares outstanding: 21.9M.

  • Trailing P/E: −1.7×; forward P/E: −1.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Aardvark Therapeutics, Inc. employs 28 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

AARD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AARDAardvark Therapeutics, Inc.$110.7M
17
GNLXGenelux Corp.$111.3M
22
BDTXBlack Diamond Therapeutics, Inc.$113.5M
57
SEERSeer, Inc. (California)$109.7M
72
VANIVivani Medical, Inc.$114.6M
39
RANIRani Therapeutics Holdings, Inc.$114.9M
62
ENGNenGene Therapeutics, Inc.$116.2M
23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aardvark Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AARD news & analysis

Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PRNewsWire · 11 Sept 2026negative

The Law Offices of Howard G. Smith announced that Aardvark Therapeutics, Inc. (AARD) shareholders who lost money have the opportunity to lead a securities fraud lawsuit. The announcement was made via a press release dated September 11, 2026.

Why it matters — AARD watchers would care because the notice signals potential securities fraud allegations against the company that could lead to legal and financial consequences.

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

GlobeNewsWire · 11 Sept 2026negative

Law firm SBS has reminded investors of a class action lawsuit against Aardvark Therapeutics alleging violations of federal securities laws, specifically Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The firm is inviting investors to lead the securities fraud lawsuit.

Why it matters — Aardvark shareholders may be affected by the securities fraud litigation and the window for participating in or leading the class action.

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit

PRNewsWire · 11 Sept 2026negative

Rosen Law Firm reminded investors in Aardvark Therapeutics that the lead plaintiff deadline in a securities fraud lawsuit is October 13, 2026. The notice applies to purchasers of AARD common stock from the company's February 13, 2025 IPO and/or securities bought during the class period ending May 14, 2026.

Why it matters — AARD watchers would care because the firm is alerting investors to an active securities fraud lawsuit and an upcoming deadline to seek lead plaintiff status.

Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PRNewsWire · 10 Sept 2026negative

The Law Offices of Frank R. announced that Aardvark Therapeutics, Inc. (AARD) shareholders who lost money have an opportunity to lead a securities fraud lawsuit against the company. The notice was issued from Los Angeles on September 10, 2026.

Why it matters — The notice signals that AARD is facing potential securities fraud litigation, which AARD watchers should track for legal and reputational implications.

FAQ

Frequently asked questions about AARD stock

What is the AARD stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Aardvark Therapeutics, Inc. have a median 12-month price target of $6, with estimates ranging from $3 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AARD stock a buy right now?

Of the 12 analysts covering Aardvark Therapeutics, Inc., 6 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Aardvark Therapeutics, Inc. 17 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AARD?

As at 12 Sept 2026, Aardvark Therapeutics, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (74 of 100).

Will AARD stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +18.6% from the last close, and Ticker Nerd's factor model ranks Aardvark Therapeutics, Inc. 17 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AARD stock forecast for 2030?

No analyst covering Aardvark Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AARD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $28 over the next 12 months.

How has AARD stock performed over the past year?

Aardvark Therapeutics, Inc. returned -35.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aardvark Therapeutics, Inc. do?

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for metabolic diseases and hunger-related conditions.

What is the latest news on AARD?

The most recent item we track (PRNewsWire, 11 Sept 2026): "Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit". The Law Offices of Howard G. Smith announced that Aardvark Therapeutics, Inc. (AARD) shareholders who lost money have the opportunity to lead a securities fraud lawsuit. The announcement was made via a press release dated September 11, 2026.

Company

About Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for metabolic diseases and hunger-related conditions. The company’s current work centers on oral, gut-restricted drug candidates designed to activate bitter taste receptors in the digestive tract and influence satiety signaling through the gut-brain axis. Its lead program, ARD-101, is being developed for hyperphagia associated with Prader-Willi syndrome and other hunger-associated rare diseases, while additional programs explore applications in obesity and related metabolic disorders. Aardvark Therapeutics operates in the biopharmaceutical and health technology sectors, with a research-driven model built around advancing investigational therapies through clinical development for conditions with limited treatment options. Founded in 2017 and headquartered in San Diego, California, the company focuses on translating its proprietary science into targeted treatments for patients affected by metabolic and inflammatory disease pathways.

CEO Dr. Tien-Li Lee M.D. · 28 employees · United States · https://aardvarktherapeutics.com